Cargando…
The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide
Paracoccidioidomycosis (PCM), a common chronic mycosis in Latin America, is a granulomatous systemic disease caused by the thermo-dimorphic fungus Paracoccidioides brasiliensis. The glycoprotein gp43 is the main antigen target of P. brasiliensis and a 15-mer internal peptide (QTLIAIHTLAIRYAN), known...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343455/ https://www.ncbi.nlm.nih.gov/pubmed/22586420 http://dx.doi.org/10.3389/fmicb.2012.00154 |
_version_ | 1782231828208287744 |
---|---|
author | Mayorga, Oriana Muñoz, Julian E. Lincopan, Nilton Teixeira, Aline F. Ferreira, Luis C. S. Travassos, Luiz R. Taborda, Carlos P. |
author_facet | Mayorga, Oriana Muñoz, Julian E. Lincopan, Nilton Teixeira, Aline F. Ferreira, Luis C. S. Travassos, Luiz R. Taborda, Carlos P. |
author_sort | Mayorga, Oriana |
collection | PubMed |
description | Paracoccidioidomycosis (PCM), a common chronic mycosis in Latin America, is a granulomatous systemic disease caused by the thermo-dimorphic fungus Paracoccidioides brasiliensis. The glycoprotein gp43 is the main antigen target of P. brasiliensis and a 15-mer internal peptide (QTLIAIHTLAIRYAN), known as P10, defines a major CD4(+)-specific T cell epitope. Previous results have indicated that, besides having a preventive role in conventional immunizations prior to challenge with the fungus, protective anti-fungal effects can be induced in P. brasiliensis-infected mice treated with P10 administered with complete Freund’s adjuvant (CFA). The peptide elicits an IFN-γ-dependent Th1 immune response and is the main candidate for effective immunotherapy of patients with PCM, as an adjunctive approach to conventional chemotherapy. In the present study we tested the therapeutic effects of P10 combined with different adjuvants [aluminum hydroxide, CFA, flagellin, and the cationic lipid dioctadecyl-dimethylammonium bromide (DODAB)] in BALB/c mice previously infected with the P. brasiliensis Pb18 strain. Significant reductions in the number of colony forming units of the fungus were detected in lungs of mice immunized with P10 associated with the different adjuvants 52 days after infection. Mice treated with DODAB and P10, followed by mice treated with P10 and flagellin, showed the most prominent effects as demonstrated by the lowest numbers of viable yeast cells as well as reductions in granuloma formation and fibrosis. Concomitantly, secretion of IFN-γ and TNF-α, in contrast to interleukin (IL)-4 and IL-10, was enhanced in the lungs of mice immunized with P10 in combination with the tested adjuvants, with the best results observed in mice treated with P10 and DODAB. In conclusion, the present results demonstrate that the co-administration of the synthetic P10 peptide with several adjuvants, particularly DODAB, have significant therapeutic effects in experimental PCM. |
format | Online Article Text |
id | pubmed-3343455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Frontiers Research Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33434552012-05-14 The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide Mayorga, Oriana Muñoz, Julian E. Lincopan, Nilton Teixeira, Aline F. Ferreira, Luis C. S. Travassos, Luiz R. Taborda, Carlos P. Front Microbiol Microbiology Paracoccidioidomycosis (PCM), a common chronic mycosis in Latin America, is a granulomatous systemic disease caused by the thermo-dimorphic fungus Paracoccidioides brasiliensis. The glycoprotein gp43 is the main antigen target of P. brasiliensis and a 15-mer internal peptide (QTLIAIHTLAIRYAN), known as P10, defines a major CD4(+)-specific T cell epitope. Previous results have indicated that, besides having a preventive role in conventional immunizations prior to challenge with the fungus, protective anti-fungal effects can be induced in P. brasiliensis-infected mice treated with P10 administered with complete Freund’s adjuvant (CFA). The peptide elicits an IFN-γ-dependent Th1 immune response and is the main candidate for effective immunotherapy of patients with PCM, as an adjunctive approach to conventional chemotherapy. In the present study we tested the therapeutic effects of P10 combined with different adjuvants [aluminum hydroxide, CFA, flagellin, and the cationic lipid dioctadecyl-dimethylammonium bromide (DODAB)] in BALB/c mice previously infected with the P. brasiliensis Pb18 strain. Significant reductions in the number of colony forming units of the fungus were detected in lungs of mice immunized with P10 associated with the different adjuvants 52 days after infection. Mice treated with DODAB and P10, followed by mice treated with P10 and flagellin, showed the most prominent effects as demonstrated by the lowest numbers of viable yeast cells as well as reductions in granuloma formation and fibrosis. Concomitantly, secretion of IFN-γ and TNF-α, in contrast to interleukin (IL)-4 and IL-10, was enhanced in the lungs of mice immunized with P10 in combination with the tested adjuvants, with the best results observed in mice treated with P10 and DODAB. In conclusion, the present results demonstrate that the co-administration of the synthetic P10 peptide with several adjuvants, particularly DODAB, have significant therapeutic effects in experimental PCM. Frontiers Research Foundation 2012-05-04 /pmc/articles/PMC3343455/ /pubmed/22586420 http://dx.doi.org/10.3389/fmicb.2012.00154 Text en Copyright © Mayorga, Muñoz, Lincopan, Teixeira, Ferreira, Travassos and Taborda. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) , which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited. |
spellingShingle | Microbiology Mayorga, Oriana Muñoz, Julian E. Lincopan, Nilton Teixeira, Aline F. Ferreira, Luis C. S. Travassos, Luiz R. Taborda, Carlos P. The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide |
title | The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide |
title_full | The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide |
title_fullStr | The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide |
title_full_unstemmed | The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide |
title_short | The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide |
title_sort | role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the p10 peptide |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343455/ https://www.ncbi.nlm.nih.gov/pubmed/22586420 http://dx.doi.org/10.3389/fmicb.2012.00154 |
work_keys_str_mv | AT mayorgaoriana theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT munozjuliane theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT lincopannilton theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT teixeiraalinef theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT ferreiraluiscs theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT travassosluizr theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT tabordacarlosp theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT mayorgaoriana roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT munozjuliane roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT lincopannilton roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT teixeiraalinef roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT ferreiraluiscs roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT travassosluizr roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide AT tabordacarlosp roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide |